PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 185 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 2.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,482,827 | -39.1% | 667,628 | -20.4% | 0.03% | -37.5% |
Q2 2023 | $33,616,125 | +21.2% | 838,935 | +23.4% | 0.05% | +17.1% |
Q1 2023 | $27,737,618 | +5.4% | 679,677 | -0.3% | 0.04% | -2.4% |
Q4 2022 | $26,308,661 | -27.6% | 681,395 | -0.3% | 0.04% | -30.0% |
Q3 2022 | $36,346,000 | +8.1% | 683,327 | +18.5% | 0.06% | +17.6% |
Q2 2022 | $33,612,000 | -36.2% | 576,530 | -17.2% | 0.05% | -27.1% |
Q1 2022 | $52,660,000 | +35.9% | 695,913 | +8.0% | 0.07% | +37.3% |
Q4 2021 | $38,759,000 | +42.2% | 644,162 | +32.4% | 0.05% | +21.4% |
Q3 2021 | $27,254,000 | -19.9% | 486,675 | -13.2% | 0.04% | -2.3% |
Q2 2021 | $34,004,000 | -14.3% | 560,386 | -1.0% | 0.04% | -15.7% |
Q1 2021 | $39,667,000 | -34.9% | 565,947 | -44.4% | 0.05% | +18.6% |
Q4 2020 | $60,958,000 | +73.7% | 1,018,660 | +73.0% | 0.04% | -23.2% |
Q3 2020 | $35,094,000 | -1.6% | 588,920 | -13.3% | 0.06% | -13.8% |
Q2 2020 | $35,655,000 | +36.0% | 679,534 | -17.0% | 0.06% | +16.1% |
Q1 2020 | $26,213,000 | -36.4% | 819,168 | -10.0% | 0.06% | -16.4% |
Q4 2019 | $41,223,000 | +30.2% | 910,008 | +14.9% | 0.07% | +19.6% |
Q3 2019 | $31,669,000 | -0.6% | 791,717 | +8.1% | 0.06% | -3.4% |
Q2 2019 | $31,855,000 | +15.7% | 732,473 | +1.2% | 0.06% | +18.4% |
Q1 2019 | $27,537,000 | -34.8% | 723,518 | -26.3% | 0.05% | -35.5% |
Q4 2018 | $42,208,000 | -12.2% | 981,135 | +0.3% | 0.08% | -8.4% |
Q3 2018 | $48,076,000 | +23.4% | 978,154 | -22.1% | 0.08% | +22.1% |
Q2 2018 | $38,969,000 | +2.1% | 1,255,030 | +2.4% | 0.07% | +3.0% |
Q1 2018 | $38,184,000 | -14.7% | 1,225,807 | +25.1% | 0.07% | -9.6% |
Q4 2017 | $44,746,000 | +22.0% | 980,206 | +3.5% | 0.07% | +14.1% |
Q3 2017 | $36,665,000 | -18.7% | 947,405 | +1.3% | 0.06% | -21.0% |
Q2 2017 | $45,075,000 | -47.1% | 935,168 | -49.6% | 0.08% | +5.2% |
Q1 2017 | $85,146,000 | +249.6% | 1,857,054 | +146.3% | 0.08% | +63.8% |
Q4 2016 | $24,355,000 | +7.3% | 754,022 | +13.7% | 0.05% | +11.9% |
Q3 2016 | $22,703,000 | +40.5% | 663,456 | +38.5% | 0.04% | +31.2% |
Q2 2016 | $16,163,000 | – | 479,200 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |